サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1413124

ニューロサイエンス市場：タイプ別、エンドユーザー別-2024-2030年の世界予測

Neuroscience Market by Type (Diagnostic Solution, Drug Therapy, Non-drug Therapy), End-User (Diagnostic Laboratories, Hospitals, Research & Academic Institutes) - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 185 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ニューロサイエンス市場：タイプ別、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 185 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ニューロサイエンス市場規模は2023年に137億7,000万米ドルと推定され、2024年には151億1,000万米ドルに達し、CAGR 10.34%で2030年には274億2,000万米ドルに達すると予測されます。

ニューロサイエンスの世界市場

主な市場の統計
基準年[2023］ 137億7,000万米ドル
予測年[2024] 151億1,000万米ドル
予測年 [2030] 274億2,000万米ドル
CAGR（%） 10.34%
ニューロサイエンス Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはニューロサイエンス市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、ニューロサイエンス市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-ニューロサイエンス市場の市場規模および予測は？

2-ニューロサイエンス市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-ニューロサイエンス市場における技術動向と規制の枠組みは？

4-ニューロサイエンス市場における主要ベンダーの市場シェアは？

5-ニューロサイエンス市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で神経疾患の有病率が増加
      • 神経疾患に対する創薬と開発の増加
      • 脳の健康と認知機能を強化するためにニューロサイエンスの使用が増加
    • 抑制要因
      • ニューロサイエンスの調査に伴う高額な費用
    • 機会
      • 個別化医療の開発におけるニューロサイエンスの新たな使用法
      • ニューロサイエンス調査に有利な資金調達情勢
    • 課題
      • ニューロテクノロジーの使用に伴う機能上の制限
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 ニューロサイエンス市場：タイプ別

  • 診断ソリューション
    • 分子
      • 免疫測定法
      • 機器
      • キットと消耗品
      • 液体クロマトグラフィー
      • PCR
      • シーケンス
      • ソフトウェア
    • 非分子
      • 脳幹聴覚誘発電位
      • 脳波検査
      • イメージング
  • 薬物セラピー
    • 神経学的障害
      • アルツハイマー病
      • てんかん
      • ハンチントン病
      • 多発性硬化症
      • パーキンソン病
      • 血管性認知症
    • 精神神経障害
      • 不安
      • 注意欠陥
      • 自閉症スペクトラム
      • 不眠症
      • 気分障害
      • 薬物乱用
  • 非薬物療法
    • 行動療法
      • 動物介助
      • ホームベース
      • 入院患者
      • 外来
    • デジタルヘルスサービス

第7章 ニューロサイエンス市場：エンドユーザー別

  • 診断研究所
  • 病院
  • 調査および学術機関

第8章 南北アメリカのニューロサイエンス市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域のニューロサイエンス市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカのニューロサイエンス市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Agilent Technologies, Inc.
    • Bayer AG
    • Bio-Rad Laboratories, Inc.
    • Brain Products GmbH
    • Compumedics Limited
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Gilson, Inc.
    • GL Sciences Inc.
    • Hitachi, Ltd.
    • Illumina, Inc.
    • JASCO Corporation
    • Merck KGaA
    • Metrohm AG
    • Natus Medical Incorporated
    • Novasep Holding SAS
    • PerkinElmer Inc.
    • Pfizer Inc.
    • Promega Corporation
    • QIAGEN GmbH
    • Restek Corporation
    • Shimadzu Corporation
    • Siemens AG
    • Thermo Fisher Scientific Inc.
    • Waters Corporation
    • YMC Co., Ltd.
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. NEUROSCIENCE MARKET RESEARCH PROCESS
  • FIGURE 2. NEUROSCIENCE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. NEUROSCIENCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. NEUROSCIENCE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. NEUROSCIENCE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. NEUROSCIENCE MARKET DYNAMICS
  • FIGURE 7. NEUROSCIENCE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. NEUROSCIENCE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. NEUROSCIENCE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 10. NEUROSCIENCE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES NEUROSCIENCE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES NEUROSCIENCE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. NEUROSCIENCE MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. NEUROSCIENCE MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. NEUROSCIENCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. NEUROSCIENCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 8. NEUROSCIENCE MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 10. NEUROSCIENCE MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. NEUROSCIENCE MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. NEUROSCIENCE MARKET SIZE, BY KITS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. NEUROSCIENCE MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. NEUROSCIENCE MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. NEUROSCIENCE MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 19. NEUROSCIENCE MARKET SIZE, BY BRAINSTEM AUDITORY EVOKED POTENTIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. NEUROSCIENCE MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 24. NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 26. NEUROSCIENCE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. NEUROSCIENCE MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. NEUROSCIENCE MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. NEUROSCIENCE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. NEUROSCIENCE MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. NEUROSCIENCE MARKET SIZE, BY VASCULAR DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 34. NEUROSCIENCE MARKET SIZE, BY ANXIETY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. NEUROSCIENCE MARKET SIZE, BY ATTENTION DEFICIT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. NEUROSCIENCE MARKET SIZE, BY AUTISM SPECTRUM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. NEUROSCIENCE MARKET SIZE, BY INSOMNIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. NEUROSCIENCE MARKET SIZE, BY MOOD DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. NEUROSCIENCE MARKET SIZE, BY SUBSTANCE ABUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 42. NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 44. NEUROSCIENCE MARKET SIZE, BY ANIMAL-ASSISTED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. NEUROSCIENCE MARKET SIZE, BY HOME-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. NEUROSCIENCE MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. NEUROSCIENCE MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. NEUROSCIENCE MARKET SIZE, BY DIGITAL HEALTH SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. NEUROSCIENCE MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES NEUROSCIENCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 204. SINGAPORE NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 205. SINGAPORE NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 224. TAIWAN NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 225. TAIWAN NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 232. THAILAND NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. THAILAND NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 235. THAILAND NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 242. VIETNAM NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 243. VIETNAM NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 244. VIETNAM NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 245. VIETNAM NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 263. DENMARK NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 264. DENMARK NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 265. DENMARK NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 266. DENMARK NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 273. EGYPT NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 274. EGYPT NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 275. EGYPT NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 276. EGYPT NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 283. FINLAND NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 284. FINLAND NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 285. FINLAND NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 286. FINLAND NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 292. FRANCE NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 293. FRANCE NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 294. FRANCE NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 295. FRANCE NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 296. FRANCE NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 300. GERMANY NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 301. GERMANY NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 302. GERMANY NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 303. GERMANY NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 304. GERMANY NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 305. GERMANY NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 306. GERMANY NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 310. ISRAEL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 311. ISRAEL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 312. ISRAEL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 313. ISRAEL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 314. ISRAEL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 315. ISRAEL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 316. ISRAEL NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 320. ITALY NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 321. ITALY NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 322. ITALY NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 323. ITALY NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 324. ITALY NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 325. ITALY NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 326. ITALY NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 330. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 332. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 334. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 336. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 337. NIGERIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 338. NIGERIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 340. NIGERIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 341. NIGERIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 342. NIGERIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 343. NIGERIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 344. NIGERIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 345. NIGERIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 346. NIGERIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 347. NORWAY NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 348. NORWAY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 349. NORWAY NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 350. NORWAY NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 351. NORWAY NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 352. NORWAY NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 353. NORWAY NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 354. NORWAY NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 355. NORWAY NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 356. NORWAY NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 357. POLAND NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 358. POLAND NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 359. POLAND NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 360. POLAND NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 361. POLAND NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 362. POLAND NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 363. POLAND NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 364. POLAND NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 365. POLAND NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 366. POLAND NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 367. QATAR NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)

TABL

目次
Product Code: MRR-C002B1C9958C

[185 Pages Report] The Neuroscience Market size was estimated at USD 13.77 billion in 2023 and expected to reach USD 15.11 billion in 2024, at a CAGR 10.34% to reach USD 27.42 billion by 2030.

Global Neuroscience Market

KEY MARKET STATISTICS
Base Year [2023] USD 13.77 billion
Estimated Year [2024] USD 15.11 billion
Forecast Year [2030] USD 27.42 billion
CAGR (%) 10.34%
Neuroscience Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Neuroscience Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Neuroscience Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Neuroscience Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Bayer AG, Bio-Rad Laboratories, Inc., Brain Products GmbH, Compumedics Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilson, Inc., GL Sciences Inc., Hitachi, Ltd., Illumina, Inc., JASCO Corporation, Merck KGaA, Metrohm AG, Natus Medical Incorporated, Novasep Holding SAS, PerkinElmer Inc., Pfizer Inc., Promega Corporation, QIAGEN GmbH, Restek Corporation, Shimadzu Corporation, Siemens AG, Thermo Fisher Scientific Inc., Waters Corporation, and YMC Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Neuroscience Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Diagnostic Solution
      • Molecular
        • Immunoassay
        • Instruments
        • Kits & Consumables
        • Liquid Chromatography
        • PCR
        • Sequencing
        • Software
      • Non-molecular
        • Brainstem auditory evoked potential
        • Electroencephalography
        • Imaging
    • Drug Therapy
      • Neurological disorders
        • Alzheimer's disease
        • Epilepsy
        • Huntington's disease
        • Multiple sclerosis
        • Parkinson's disease
        • Vascular dementia
      • Neuropsychiatric disorders
        • Anxiety
        • Attention deficit
        • Autism spectrum
        • Insomnia
        • Mood disorder
        • Substance abuse
    • Non-drug Therapy
      • Behavioral Therapy
        • Animal-assisted
        • Home-based
        • Inpatient
        • Outpatient
      • Digital Health Services
  • End-User
    • Diagnostic Laboratories
    • Hospitals
    • Research & Academic Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Neuroscience Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Neuroscience Market?

3. What are the technology trends and regulatory frameworks in the Neuroscience Market?

4. What is the market share of the leading vendors in the Neuroscience Market?

5. Which modes and strategic moves are suitable for entering the Neuroscience Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Neuroscience Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of neurological disorders worldwide
      • 5.1.1.2. Rise in drug discovery and development for neurological conditions
      • 5.1.1.3. Increasing use of neuroscience to enhance brain health and cognitive functions
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with neuroscience research
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging use of neuroscience in the development of personalized medicine
      • 5.1.3.2. Favorable funding landscape for neuroscience research
    • 5.1.4. Challenges
      • 5.1.4.1. Functional limitations pertaining to the use of neurotechnologies
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Neuroscience Market, by Type

  • 6.1. Introduction
  • 6.2. Diagnostic Solution
    • 6.3.1. Molecular
      • 6.3.2.1. Immunoassay
      • 6.3.2.2. Instruments
      • 6.3.2.3. Kits & Consumables
      • 6.3.2.4. Liquid Chromatography
      • 6.3.2.5. PCR
      • 6.3.2.6. Sequencing
      • 6.3.2.7. Software
    • 6.3.2. Non-molecular
      • 6.3.3.1. Brainstem auditory evoked potential
      • 6.3.3.2. Electroencephalography
      • 6.3.3.3. Imaging
  • 6.3. Drug Therapy
    • 6.4.1. Neurological disorders
      • 6.4.2.1. Alzheimer's disease
      • 6.4.2.2. Epilepsy
      • 6.4.2.3. Huntington's disease
      • 6.4.2.4. Multiple sclerosis
      • 6.4.2.5. Parkinson's disease
      • 6.4.2.6. Vascular dementia
    • 6.4.2. Neuropsychiatric disorders
      • 6.4.3.1. Anxiety
      • 6.4.3.2. Attention deficit
      • 6.4.3.3. Autism spectrum
      • 6.4.3.4. Insomnia
      • 6.4.3.5. Mood disorder
      • 6.4.3.6. Substance abuse
  • 6.4. Non-drug Therapy
    • 6.5.1. Behavioral Therapy
      • 6.5.2.1. Animal-assisted
      • 6.5.2.2. Home-based
      • 6.5.2.3. Inpatient
      • 6.5.2.4. Outpatient
    • 6.5.2. Digital Health Services

7. Neuroscience Market, by End-User

  • 7.1. Introduction
  • 7.2. Diagnostic Laboratories
  • 7.3. Hospitals
  • 7.4. Research & Academic Institutes

8. Americas Neuroscience Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Neuroscience Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Neuroscience Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Agilent Technologies, Inc.
    • 12.1.2. Bayer AG
    • 12.1.3. Bio-Rad Laboratories, Inc.
    • 12.1.4. Brain Products GmbH
    • 12.1.5. Compumedics Limited
    • 12.1.6. Eli Lilly and Company
    • 12.1.7. F. Hoffmann-La Roche Ltd.
    • 12.1.8. Gilson, Inc.
    • 12.1.9. GL Sciences Inc.
    • 12.1.10. Hitachi, Ltd.
    • 12.1.11. Illumina, Inc.
    • 12.1.12. JASCO Corporation
    • 12.1.13. Merck KGaA
    • 12.1.14. Metrohm AG
    • 12.1.15. Natus Medical Incorporated
    • 12.1.16. Novasep Holding SAS
    • 12.1.17. PerkinElmer Inc.
    • 12.1.18. Pfizer Inc.
    • 12.1.19. Promega Corporation
    • 12.1.20. QIAGEN GmbH
    • 12.1.21. Restek Corporation
    • 12.1.22. Shimadzu Corporation
    • 12.1.23. Siemens AG
    • 12.1.24. Thermo Fisher Scientific Inc.
    • 12.1.25. Waters Corporation
    • 12.1.26. YMC Co., Ltd.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing